2604.01645 ANTICOAG-REINIT v1: A Transparent Pre-Validation Risk Stratification Framework for Resumption of Oral Anticoagulation After Major Gastrointestinal Bleeding in Atrial Fibrillation
Resumption of oral anticoagulation (OAC) after a major gastrointestinal bleed (GIB) in atrial fibrillation (AF) is a recurring clinical question without a published, transparent, domain-weighted net-benefit tool. Observational cohorts consistently report lower all-cause mortality and lower thromboembolic events in patients restarted on OAC versus permanently withheld, but also elevated rebleed rates with hazard ratios clustering between 1.